.TableClas{FONT-FAMILY:Arial; FONT -SIZE: 12px;}.BottomBrd{BACKGROUND-COLOR:#DFE1B6; BORDER-BOTTOM:#787962 1px solid;}.FontBg{FONT-FAMILY: Arial; FONT-SIZE: 12px; COLOR: #000000; BACKGROUND-COLOR: #EEEEDA;}.FontBg1{FONT-FAMILY: Arial; FONT-SIZE: 12px; COLOR: #000000; BACKGROUND-COLOR: #FFFFFF;}.FstFontBg{FONT-FAMILY: Arial; FONT-SIZE: 12px; COLOR: #000000; BACKGROUND-COLOR: #FFFFE3;}.FstTrfont{FONT-FAMILY: Arial; FONT-SIZE: 12px; COLOR: #F8F8E3;}.Caption{FONT-FAMILY: Arial; FONT-SIZE: 11px; FONT-WEIGHT: bold;}.heading{FONT-FAMILY: Arial; FONT-SIZE: 18px; FONT-WEIGHT: bold; COLOR: #0253B7;}.byline{FONT-FAMILY: Arial; FONT-SIZE: 12px;}.author{FONT-FAMILY: Arial; FONT-SIZE: 11px; FONT-WEIGHT: bold;}Morepen scraps biotech foray, Nasdaq listing plansBHUPESH BHANDARI / BSCAL July 21,2000
